iLABMED最新文献

{"title":"An iASPP-derived short peptide restores p53-mediated cell death in cancers with wild-type p53","authors":"Shi Qiu,&nbsp;Wei Qi,&nbsp;Wen Wu,&nbsp;Qian Qiu,&nbsp;Jiali Ma,&nbsp;Yingjun Li,&nbsp;Wenhui Fan,&nbsp;Junli Li,&nbsp;Yang Xu,&nbsp;Hai Chen,&nbsp;Jie Liu","doi":"10.1002/ila2.21","DOIUrl":"https://doi.org/10.1002/ila2.21","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is an evolutionarily conserved p53 inhibitor. Mechanistically, iASPP can accelerate tumorigenesis by inhibiting the transactivation function of p53. Targeting the interaction between iASPP and p53 may be a potential therapy for restoring the activity of p53 in tumors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We constructed an iASPP-derived peptide, called A8, that was derived from the C-terminus of iASPP. Here, we transfected A8 into two wild-type (WT) p53 cell lines, U2OS and A549, and then determined the number of apoptotic cells. The mechanism by which A8 affected apoptosis was further examined by immunoprecipitation (IP), Dual-Luciferase reporter assays, and chromatin IP assays. Real-time polymerase chain reaction and western blots were also used to examine the expression levels of apoptosis-related factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our data demonstrate that A8 can increase apoptosis rates in WT p53 cell lines. Functional analysis suggested that A8 restored the transcriptional function and DNA binding activities of p53 toward the Bax and PUMA gene promoters. Moreover, A8 reduced cell proliferation and inhibited tumor growth in xenograft nude mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These data provide a new approach for restoring the tumor suppressor function of p53 in cancer cells that express WT p53 and therefore may serve as a novel cancer treatment strategy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 2","pages":"121-131"},"PeriodicalIF":0.0,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50149438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence of liver abnormalities is higher in inactive hepatitis B virus carriers with influenza A infection","authors":"Liqin Sun,&nbsp;Yong-Mei Yin,&nbsp;Nan Xiao,&nbsp;Cheng Wang,&nbsp;Xiao-Guang Li,&nbsp;Jun Wang,&nbsp;Hongzhou Lu","doi":"10.1002/ila2.20","DOIUrl":"https://doi.org/10.1002/ila2.20","url":null,"abstract":"<p>Influenza A infection leads to a higher incidence of liver injury in HBV carriers than in patients infected with influenza A alone. Moreover, HBV carriers experience earlier onset and greater severity of liver injury than individuals with only influenza A.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 2","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50146667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of autoantibody detection in chronic liver disease","authors":"Jinyu Han,&nbsp;Jin Chen,&nbsp;Yajie Wang","doi":"10.1002/ila2.18","DOIUrl":"https://doi.org/10.1002/ila2.18","url":null,"abstract":"<p>Autoantibody (AAb) detection has become one of the standards of diagnosis for autoimmune liver disease (AILD), and some AAbs have become specific biomarkers of AILD. In addition, AAbs can be detected in patients with non-AILDs, such as viral hepatitis and alcoholic liver disease. However, the distribution characteristics and pathogenic mechanisms of AAbs in patients with non-AILD are unclear. This article summarizes the characteristics of AAbs in several common clinical chronic liver diseases (CLDs) and discusses the value of AAb analysis in CLD.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 2","pages":"103-108"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50132894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interim proposal for collecting and handling of microbiology specimens from patients with COVID-19 in general hospitals","authors":"Zhaofang Jiang,&nbsp;Shan Chen,&nbsp;Jiayao Qu,&nbsp;Siyuan Liu,&nbsp;Tao Hong,&nbsp;Houming Liu,&nbsp;Yi-Wei Tang,&nbsp;Jiuxin Qu,&nbsp;Hongzhou Lu","doi":"10.1002/ila2.13","DOIUrl":"https://doi.org/10.1002/ila2.13","url":null,"abstract":"<p>SARS-CoV-2 infections have an increased risk of developing severe disease and a variety of secondary bacterial or fungal infections, and the types of microbiology testing of specimens vary accordingly. A standardized process of specimen collection and handling contributes to the correct diagnosis and treatment of patients with COVID-19.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50148021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target selection and clinical chimeric antigen receptor T cell activity against solid tumors","authors":"Eric von Hofe,&nbsp;Yanping Yang,&nbsp;Moonsoo M. Jin","doi":"10.1002/ila2.8","DOIUrl":"https://doi.org/10.1002/ila2.8","url":null,"abstract":"<p>Chimeric antigen receptor (CAR) T cell therapy is a relatively new form of targeted therapy that has demonstrated impressive success in treating hematological malignancies. It has been challenging to translate this success to solid tumors. Reasons for this include barriers to delivery, tumor heterogeneity, cancer cells' ability to evade the immune system as well as identifying the optimal target. Most CAR T clinical trials have targeted well-characterized cancer targets with significant preclinical and in some cases clinical validation. Published results from some of these trials show signs of anti-cancer activity that warrant encouragement, but also caution, given instances of unacceptable toxicity. The narrow therapeutic window is complicated by the ability of CAR T cells to expand in patients regardless of dose. Here, we review those trials showing encouraging results in the context of target selection. It is clear that more specific tumor targeting is required, either by affinity tuning to avoid low-level target expression in healthy cells, logic gating, or the identification of new targets that are more cancer specific.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"29-43"},"PeriodicalIF":0.0,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50138337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of an automated digital cell morphology analysis system with manual counting","authors":"Juan Jiao,&nbsp;Xin Yin,&nbsp;Jiali Ma,&nbsp;Yinglong Xia,&nbsp;Jianxia Xu,&nbsp;Shaozhe Zhao,&nbsp;Jie Liu","doi":"10.1002/ila2.10","DOIUrl":"https://doi.org/10.1002/ila2.10","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Bionovation's CSFA800 is a new automated digital cell imaging analyzer. We evaluated the performance of the CSFA800 by comparing it with artificial peripheral blood white blood cell counting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>According to inclusion and exclusion criteria, 131 randomly selected samples (77 abnormal samples and 54 normal samples) were compared. Correlations between automated and manual counting results were analyzed. Manual counting was carried out according to the guidelines of the Association of Clinical and Laboratory Standards.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Counts of neutrophils, lymphocytes, monocytes, eosinophils, basophils, and immature granulocytes obtained from CSFA800 and artificial methods were linearly and positively correlated, with <i>R</i> values of 0.73, 0.65, 0.24, 0.2, 0.4, and 0.63, respectively, all <i>p</i> &lt; 0.05. Therefore, correlations between CSFA800 and manual counting are acceptable. Compared with the DI-60 Automated Digital Cell Morphology System (DI-60; Sysmex), CSFA800 is more efficient and can analyze 20,000 cells in 1 min. However, the overall accuracy of CSFA800 is not as good as DI-60, although its counting performance is better for basophils.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The performance of CSFA800 for WBC counts is acceptable, and it displayed good performance for neutrophils, lymphocytes, and immature granulocytes. Compared to DI-60, CSFA800 is more efficient but has slightly lower overall accuracy. To some extent, CSFA800 is helpful to optimize the clinical laboratory workflow and improve the working efficiency of inspectors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"22-28"},"PeriodicalIF":0.0,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50151804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality management in anatomic pathology: The past, present, and future","authors":"Chenguang Xi,&nbsp;Dengfeng Cao","doi":"10.1002/ila2.7","DOIUrl":"https://doi.org/10.1002/ila2.7","url":null,"abstract":"<p>One of the challenges in anatomic pathology laboratories is to meet the increasing need for pathological diagnosis, using quality management (QM) activities and systems to ensure that patients receive their accurate and timely pathology report. The aim of this paper is to review anatomic pathology QM from both management and technical perspectives, including the past, present, and future opportunities. First, the evolution of the QM concept and scope will be discussed. Next, current QM system implementation and laboratory accreditations will be discussed from the management perspective, and common medical errors in anatomic pathology in different testing cycles will be analyzed. Finally, selected future management systems to improve the level of total QM worldwide for patient safety and the potential of informatics to be used as an auxiliary tool in anatomic pathology will be discussed.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"75-81"},"PeriodicalIF":0.0,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50134426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of CRISPR/Cas systems in nucleic acid detection of infectious diseases","authors":"Jinying Dong,&nbsp;Yuguang Du,&nbsp;Lei Zhou","doi":"10.1002/ila2.6","DOIUrl":"https://doi.org/10.1002/ila2.6","url":null,"abstract":"<p>Infectious diseases are a serious threat to human health, and accurate, rapid and convenient early detection of pathogens is the first step of active treatment. Technologies that detect pathogens have advanced significantly because of the development of fundamental disciplines and the integration of multidisciplinary fields. Among these technologies, nucleic acid detection technology is preferred because of its rapid measurement, accuracy and high sensitivity. The CRISPR/Cas system, consisting of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas), is an adaptive immune system that specifically recognizes, binds and cleaves exogenous invasive nucleic acids. The CRISPR/Cas system is widely found in bacteria and archaea. Researchers have developed nucleic acid detection technologies with single-molecule sensitivity, single-base precision specificity, portability and low cost based on the specific cleavage and trans-cleavage activities of the CRISPR/Cas system. The next generation of in-vitro diagnostics is shifting to nucleic acid technology because this technology shows promise in a wide range of applications in resource-constrained environments. In this review, the development and mechanism of the CRISPR/Cas system are presented together with representative CRISPR/Cas applications in nucleic acid detection. Additionally, the review summarizes future perspectives and trends of the CRISPR/Cas system in nucleic acid detection.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"58-74"},"PeriodicalIF":0.0,"publicationDate":"2023-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50150517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bottlenecks and recent advancements in detecting Mycobacterium tuberculosis in patients with HIV","authors":"Zixun Lin,&nbsp;Liqin Sun,&nbsp;Cheng Wang,&nbsp;Fuxiang Wang,&nbsp;Jun Wang,&nbsp;Qian Li,&nbsp;Hongzhou Lu","doi":"10.1002/ila2.11","DOIUrl":"https://doi.org/10.1002/ila2.11","url":null,"abstract":"<p>Tuberculosis (TB) remains a leading cause of deaths among patients with acquired immunodeficiency syndrome patients. Early diagnosis of TB is essential for administering timely anti-TB therapy and improving health outcomes, particularly in the people living with HIV. However, conventional techniques used to detect <i>Mycobacterium tuberculosis</i> have significant drawbacks: for example, sputum smear microscopy has low sensitivity, and liquid culture is time-consuming in patients with HIV-TB co-infection due to low sputum production. In addition, while immunological-based methods involving tuberculin skin testing and interferon gamma release assays are commonly used for auxiliary TB diagnosis, they are often inaccurate in immunodeficient patients. Molecular techniques such as line probe assays, Xpert MTB, and lipoarabinomannan assay are recommended for early diagnosis by World Health Organization. However, no single technique is sufficicent for diagnosing HIV/TB co-infection, suggesting that multiple diagnostic tests should be used to detect TB. Here, we summarize the drawbacks and advantages of existing TB-diagnostic methods, as well as their applications to diagnosing HIV/TB co-infection. We describe newly emerging technologies such as whole genome sequencing and mass spectrometry, with the aim of providing updated guidelines and alternative strategies for TB diagnosis, and particularly HIV/TB diagnosis.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"44-57"},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50127959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single cell metabolic phenome and genome via the ramanome technology platform: Precision medicine of infectious diseases at the ultimate precision?","authors":"Jian Xu,&nbsp;Jianzhong Zhang,&nbsp;Yingchun Xu,&nbsp;Yi-Wei Tang,&nbsp;Bo Ma,&nbsp;Yuzhang Wu","doi":"10.1002/ila2.12","DOIUrl":"https://doi.org/10.1002/ila2.12","url":null,"abstract":"<p>Due to the limitations of existing approaches, a rapid, sensitive, accurate, comprehensive, and generally applicable strategy to diagnose and treat bacterial and fungal infections remains a major challenge. Here, based on the ramanome technology platform, we propose a culture-free, one cell resolution, phenome-genome-combined strategy called <span>s</span>ingle-<span>c</span>ell <span>i</span>dentification, <span>v</span>iability and <span>v</span>itality tests and <span>s</span>ource tracking (SCIVVS). For each cell directly extracted from a clinical specimen, the fingerprint region of the D₂O-probed single cell Raman spectrum (SCRS) enables species-level identification based on a reference SCRS database of pathogen species, whereas the C-D band accurately quantifies viability, metabolic vitality, phenotypic susceptibility to antimicrobials, and their intercellular heterogeneity. Moreover, to source track a cell, Raman-activated cell sorting followed by sequencing or cultivation proceeds, producinging an indexed, high coverage genome assembly or a pure culture from precisely one pathogenic cell. Finally, an integrated SCIVVS workflow that features automated profiling and sorting of metabolic and morphological phenomes can complete the entire process in only a few hours. Because it resolves heterogeneity for both the metabolic phenome and genome, targets functions, can be automated, and is orders-of-magnitude faster while cost-effective, SCIVVS is a new technological and data framework to diagnose and treat bacterial and fungal infections in various clinical and disease control settings.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"1 1","pages":"5-14"},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50126753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}